Get the Stockscreener App
3.66
2.40%
-0.09
Pre-market:
3.73
0.07
+1.91%
Mannkind Corp stock is traded at $3.66, with a volume of 3.84M.
It is down -2.40% in the last 24 hours and up +11.59% over the past month.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
See More
Previous Close:
$3.75
Open:
$3.75
24h Volume:
3.84M
Relative Volume:
0.68
Market Cap:
$1.13B
Revenue:
$360.78M
Net Income/Loss:
$-23.91M
P/E Ratio:
-46.86
EPS:
-0.0781
Net Cash Flow:
$13.07M
1W Performance:
+7.65%
1M Performance:
+11.59%
6M Performance:
-38.38%
1Y Performance:
-4.44%
1-Day Range:
$3.6403
$3.805
1-Week Range:
$3.375
$3.805
52-Week Range:
$2.23
$6.51
Mannkind Corp Stock (MNKD) Company Profile
Name
Mannkind Corp
Sector
Industry
Phone
818-661-5000
Address
1 CASPER STREET, DANBURY, CA
Compare MNKD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
3.66 | 1.13B | 360.78M | -23.91M | 13.07M | -0.0781 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Oct-10-25 | Initiated | Leerink Partners | Outperform |
| Jul-16-25 | Resumed | H.C. Wainwright | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-10-25 | Initiated | Wedbush | Outperform |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-10-23 | Initiated | Wedbush | Outperform |
| May-14-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-24-19 | Initiated | Oppenheimer | Outperform |
| Oct-25-19 | Initiated | Cantor Fitzgerald | Overweight |
| May-14-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Feb-28-18 | Downgrade | Maxim Group | Hold → Sell |
| Nov-01-17 | Downgrade | Maxim Group | Buy → Hold |
| Oct-10-17 | Initiated | H.C. Wainwright | Buy |
| Oct-06-17 | Reiterated | Maxim Group | Buy |
| Aug-11-17 | Initiated | Maxim Group | Buy |
| May-10-16 | Reiterated | Piper Jaffray | Underweight |
| May-10-16 | Reiterated | RBC Capital Mkts | Underperform |
| Jan-06-16 | Reiterated | Piper Jaffray | Underweight |
| Jan-06-16 | Reiterated | RBC Capital Mkts | Underperform |
| Nov-04-15 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| Sep-09-15 | Downgrade | Piper Jaffray | Neutral → Underweight |
| Aug-03-15 | Reiterated | RBC Capital Mkts | Outperform |
| May-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| May-11-15 | Reiterated | MLV & Co | Hold |
| Apr-16-15 | Reiterated | RBC Capital Mkts | Outperform |
View All
Mannkind Corp Stock (MNKD) Latest News
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story” - Yahoo Finance
7 Hidden Penny Stocks to Invest In - Insider Monkey
MannKind (MNKD) Stock And Valuation After New Afrezza And FUROSCIX Clinical Data - Yahoo Finance
MNKD Stock Price, Quote & Chart - ChartMill
MannKind (MNKD) Stock Price, News & Analysis - MarketBeat
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children - Stocktwits
Jim Cramer Says He Blessed MannKind as a Speculation Only - Insider Monkey
MannKind highlights wider role for Afrezza at ADA 2026 - The Pharma Letter
Jim Cramer Puts This Chip Stock In The 'Penalty Box,' Warns Occidental Could 'Go Down A Lot' If War Ends - Sahm
Jim Cramer Highlighted 16 Stocks Including Quantinuum, and the Market’s Appetite for New Supply - Insider Monkey
New data affirm safety and efficacy of MannKind's Afrezza inhaled insulin for children and adults with diabetes. - Pluang
MannKind Corporation Presents New Clinical Data Supporting Afrezza and FUROSCIX at ADA 2026 Scientific Sessions - Quiver Quantitative
Inhaled insulin data explore options for kids, pregnancy and pump users - Stock Titan
MannKind (MNKD) Advances Clinical Trials for Inhaled IPF Therapy - Insider Monkey
MannKind Corp stock (US5638651064): focus on valuation metrics after recent FDA and partnership news - AD HOC NEWS
Earnings call transcript: MannKind Q1 2026 sees revenue growth, stock surges - Investing.com
MNKD Stock Heads For Strongest Month In Over Three Years As FDA Catalyst Draws Closer - Stocktwits
Assessing MannKind (MNKD) Valuation After Recent Share Price Momentum And Royalty Growth Expectations - simplywall.st
MannKind develops inhaled ralinepag formulation for United Therapeutics - Investing.com
MannKind Q1 2026 slides: revenue up 15%, three catalysts ahead - Investing.com
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems - Yahoo Finance
MannKind stock surges on United Therapeutics partnership deal - Investing.com
5 Most Promising Penny Stocks According to Wall Street Analysts - Insider Monkey
MannKind (MNKD) Announces Milestones in Nintedanib DPI Development for IPF - GuruFocus
MannKind (MNKD) Announces Milestones in Nintedanib DPI Developme - GuruFocus
MannKind completes patient enrollment in nintedanib DPI trials - Investing.com
MannKind Corporation Advances Nintedanib DPI Program for IPF with Phase 1b INFLO-1 Study Data Expected in Q3 2026 - Quiver Quantitative
MannKind tests inhaled IPF drug in global trial, first data Q3 2026 - Stock Titan
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF - Yahoo Finance
FDA approves MannKind’s Afrezza inhaled insulin for children with diabetes - Investing.com
FDA clears MannKind (NASDAQ: MNKD) Afrezza use in children 6 and older - Stock Titan
MannKind Corp stock (US5638651064): Afrezza pediatric FDA approval and share price weakness draw foc - AD HOC NEWS
MannKind (MNKD) Is Up 11.5% After Afrezza Pediatric Approval And Trial ReliefHas The Bull Case Changed? - Yahoo Finance
MNKD stock eyes best month since 2022 ahead of FDA decision on pediatric diabetes treatment - MSN
symbol__ Stock Quote Price and Forecast - CNN
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market - Barchart.com
FDA approves Afrezza for children and adolescents with diabetes - Managed Healthcare Executive
US FDA approves MannKind's inhaled insulin for children - Reuters
MannKind Corporation (MNKD) Receives FDA Approval for Pediatric Use of Afrezza - GuruFocus
MannKind (MNKD) Receives FDA Nod for Pediatric Use of Afrezza - GuruFocus
Inhaled insulin for kids: MannKind hosts call on new Afrezza use - Stock Titan
MannKind wins FDA approval for inhaled insulin for children with type 1, type 2 diabetes - MassDevice
US FDA approves MannKind’s inhaled insulin for children By Reuters - Investing.com
MannKind’s Afrezza approved for children with diabetes - Investing.com
MannKind Corporation Announces FDA Approval of Afrezza® Inhalation Powder for Pediatric Use in Type 1 and Type 2 Diabetes - Quiver Quantitative
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes - The Manila Times
FDA approves first inhaled mealtime insulin for kids 6+ - Stock Titan
MannKind Corporation Files Form 8-K Announcing Regulatory Update and Company Information (May 27, 2026) - Minichart
FDA drops MannKind (NASDAQ: MNKD) Afrezza pulmonary malignancy trial demand - Stock Titan
Mannkind Corp Stock (MNKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mannkind Corp Stock (MNKD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thomson David | EVP Genl Counsel & Secretary |
May 12 '26 |
Sale |
3.29 |
3,033 |
9,979 |
826,299 |
1.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):